ADVANCED Phase II Trial of Weekly vs 3 Weekly Docetaxel and Cisplatin Followed by Gemcitabine in Non-small-cell Lung Cancer (NSCLC)
This is a multicenter, open-label, randomized phase II trial whose aim is to assess the antitumor activity of two sequential schedules of docetaxel and cisplatin followed by gemcitabine.
Carcinoma, Non-Small-Cell Lung
DRUG: Docetaxel and cisplatin followed by gemcitabine|DRUG: docetaxel and cisplatin followed by gemcitabine
overall response rate assessed by RECIST criteria., before, during and at the end of treatment
Time to progression, from the date of randomization to the date of first documented tumor progression or relapse|time to treatment failure, from the date of treatment start to the date of diagnosis of progression, withdrawal from study treatment for any reason, administraztion of other antitumor treatment, or death for any cause|overall survival, time interval from the date of randomisation to the date of death
This is a multicenter, open-label, randomized phase II trial whose aim is to assess the antitumor activity of two sequential schedules of docetaxel and cisplatin followed by gemcitabine.